Published in Diabetes on February 01, 2005
Adaptive beta-cell proliferation is severely restricted with advanced age. Diabetes (2009) 3.45
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther (2006) 2.71
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes (2008) 2.68
Insulin resistance alters islet morphology in nondiabetic humans. Diabetes (2013) 2.01
MAFA controls genes implicated in insulin biosynthesis and secretion. Diabetologia (2006) 1.80
Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord (2008) 1.60
Autophagy regulates pancreatic beta cell death in response to Pdx1 deficiency and nutrient deprivation. J Biol Chem (2009) 1.48
Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 1.45
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol (2010) 1.17
Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes (2008) 1.17
Beta cell-specific deficiency of the stimulatory G protein alpha-subunit Gsalpha leads to reduced beta cell mass and insulin-deficient diabetes. Proc Natl Acad Sci U S A (2007) 1.13
Pdx1 and other factors that regulate pancreatic beta-cell survival. Diabetes Obes Metab (2009) 1.09
Formation and regeneration of the endocrine pancreas. Curr Opin Cell Biol (2007) 1.08
Loss of Nix in Pdx1-deficient mice prevents apoptotic and necrotic β cell death and diabetes. J Clin Invest (2010) 1.02
Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol (2009) 1.01
Maintenance of β-cell maturity and plasticity in the adult pancreas: developmental biology concepts in adult physiology. Diabetes (2012) 0.99
Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass. Exp Diabetes Res (2011) 0.91
Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro. Sci Rep (2015) 0.90
Mechanisms of KGF mediated signaling in pancreatic duct cell proliferation and differentiation. PLoS One (2009) 0.89
Beta-cell protection and therapy for latent autoimmune diabetes in adults. Diabetes Care (2009) 0.89
G protein-coupled receptors as targets for anti-diabetic therapeutics. Nat Rev Drug Discov (2016) 0.83
Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice. J Diabetes Res (2015) 0.81
A simple matter of life and death-the trials of postnatal Beta-cell mass regulation. Int J Endocrinol (2012) 0.81
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. Diabetes Metab Syndr Obes (2010) 0.81
The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus. Korean Diabetes J (2010) 0.81
Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5. Mol Endocrinol (2012) 0.81
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes (2014) 0.78
Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats. Exp Biol Med (Maywood) (2015) 0.78
Exendin-4 protects mitochondria from reactive oxygen species induced apoptosis in pancreatic Beta cells. PLoS One (2013) 0.77
Hes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release. J Biol Chem (2014) 0.76
Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin. Front Physiol (2014) 0.76
Human placental lactogen (hPL-A) activates signaling pathways linked to cell survival and improves insulin secretion in human pancreatic islets. Islets (2011) 0.76
Stimulation of β-adrenergic receptors plays a protective role via increased expression of RAF-1 and PDX-1 in hyperglycemic rat pancreatic islet (RIN-m5F) cells. Arch Med Sci (2016) 0.75
GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly? Drug Des Devel Ther (2014) 0.75
GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in βIRKO mice. Diabetologia (2017) 0.75
Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 10.45
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med (2015) 6.48
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 3.57
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med (2011) 3.31
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem (2002) 3.08
Increased islet apoptosis in Pdx1+/- mice. J Clin Invest (2003) 2.91
TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem (2004) 2.84
The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab (2005) 2.71
Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes (2008) 2.68
Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab (2013) 2.60
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology (2012) 2.48
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
BMP4-BMPR1A signaling in beta cells is required for and augments glucose-stimulated insulin secretion. Cell Metab (2007) 2.39
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 2.14
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12
Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol (2003) 2.12
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest (2004) 2.11
Ptf1a determines horizontal and amacrine cell fates during mouse retinal development. Development (2006) 2.09
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest (2005) 2.01
The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology (2006) 1.97
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest (2006) 1.96
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes (2006) 1.83
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009) 1.79
Attenuated Wnt signaling perturbs pancreatic growth but not pancreatic function. Diabetes (2005) 1.75
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci (2003) 1.74
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology (2009) 1.74
Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest (2003) 1.73
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med (2013) 1.72
Tumour necrosis factor-alpha affects blood-brain barrier permeability and tight junction-associated occludin in acute liver failure. Liver Int (2010) 1.72
Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology (2005) 1.71
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes (2010) 1.71
GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes (2009) 1.69
Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes (2013) 1.64
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab (2008) 1.58
Clinical decisions. Management of type 2 diabetes. N Engl J Med (2008) 1.58
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept (2005) 1.57
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes (2003) 1.55
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 1.53
Pancreatic-duodenal homeobox 1 regulates expression of liver receptor homolog 1 during pancreas development. Mol Cell Biol (2003) 1.48
Fgf10 maintains notch activation, stimulates proliferation, and blocks differentiation of pancreatic epithelial cells. Dev Dyn (2003) 1.45
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology (2007) 1.45
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation (2012) 1.39
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes (2007) 1.39
Role of leptin in the regulation of glucagon-like peptide-1 secretion. Diabetes (2003) 1.35
Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes (2012) 1.29
Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology (2008) 1.28
Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab (2007) 1.28
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology (2003) 1.28
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. J Biol Chem (2006) 1.27
Endocrine cell clustering during human pancreas development. J Histochem Cytochem (2009) 1.26
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 1.26
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology (2008) 1.26
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25
Retinoic acid promotes the generation of pancreatic endocrine progenitor cells and their further differentiation into beta-cells. PLoS One (2008) 1.24
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes (2007) 1.24
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol (2007) 1.24
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes (2008) 1.24
MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr Patterns (2008) 1.24
Glucagon-like Peptide-2. Annu Rev Nutr (2006) 1.22
Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes (2008) 1.22
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens (2009) 1.21
Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology (2007) 1.20
sox4b is a key player of pancreatic alpha cell differentiation in zebrafish. Dev Biol (2005) 1.20
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
Cytokines tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem (2011) 1.20
Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. Endocrinology (2011) 1.19
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology (2009) 1.17
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes (2012) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol (2014) 1.16
Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes (2005) 1.16
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.15
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology (2009) 1.15
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology (2008) 1.10
Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes (2011) 1.10
Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes (2009) 1.10
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology (2004) 1.09
Nestin is expressed in mesenchymal and not epithelial cells of the developing mouse pancreas. Mech Dev (2002) 1.08